Biotech companies have quietly—or not so quietly, depending on your focus—been doing phenomenally well over the last couple of years. According to data in the PitchBook Platform, 549 U.S. biotech companies have raised a total of $10.6 billion since January 1, 2013. On top of that, there have been 119 exits totaling $17.3 billion, 63 of which were IPOs. The activity and success seen in the venture-backed biotech space has trickled down to the compensation of the executive teams and scientists running these companies.
To see current compensation levels for biotech CEOs, CFOs, chief medical officers and chief business officers, click here.